Business
Tactile Systems Technology, Inc. Reports First Quarter 2025 Financial Results
MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Summary & Recent Business Highlights: Total revenue increased 0.3% year-over-year to $61.3 millionGross margin of 74% versus 71% in Q1 2024Net loss of $3.0 million versus $2.2 million in Q1
About this update from Tactile Systems Technology, Inc.
[{"type":"image","alt":"Tactile Systems Technology, Inc.","displaySize":"","headline":null,"caption":"Tactile Systems Technology, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/5d5d3b18d09d63bf9ad916a0003b0c3d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pzqO_QDvQFXBZjsCmHta1A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5d5d3b18d09d63bf9ad916a0003b0c3d","width":300,"height":150}},"lazy":false},{"type":"text","content":"MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2025.","length":290,"tagName":"p"},{"type":"text","content":"First Quarter 2025 Summary & Recent Business Highlights:","length":60,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue increased 0.3% year-over-year to $61.3 million","length":60,"tagName":"p"}]},{"val":[{"type":"text","content":"Gross margin of 74% versus 71% in Q1 2024","length":41,"tagName":"p"}]},{"val":[{"type":"text","content":"Net loss of $3.0 million versus $2.2 million in Q1 2024","length":55,"tagName":"p"}]},{"val":[{"type":"text","content":"Adjusted EBITDA loss of $0.3 million versus positive Adjusted EBITDA of $1.0 million in Q1 2024","length":95,"tagName":"p"}]},{"val":[{"type":"text","content":"Repurchased $10.0 million of stock under the Company’s share repurchase program","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Expanded launch of Nimbl to include patients with lower extremity conditions, the largest segment of the lymphedema market","length":122,"tagName":"p"}]},{"val":[{"type":"text","content":"Completed launch of a new customer relationship management (CRM) tool and previously announced optimization of sales organization","length":129,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":581,"olType":false},{"type":"text","content":"“Through the first quarter our team executed on several highly strategic, growth-oriented priorities. We launched Nimbl for lower extremity lymphedema, completed efforts to optimize our sales organization for scale and efficie...